INDP RSI Chart
Last 7 days
7.4%
Last 30 days
-13.2%
Last 90 days
41.7%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 14, 2023 | anderson glen r. | bought | 56,005 | 2.34 | 23,934 | - |
Aug 11, 2023 | anderson glen r. | bought | 74,335 | 2.12 | 35,064 | - |
Aug 10, 2023 | anderson glen r. | bought | 86,046 | 1.94 | 44,354 | - |
Dec 01, 2022 | litchev boyan vesselinov | bought | 935 | 1.8709 | 500 | chief medical officer |
Nov 22, 2022 | litchev boyan vesselinov | bought | 915 | 1.83 | 500 | chief medical officer |
Nov 21, 2022 | meckler jeffrey a | bought | 18,240 | 1.9 | 9,600 | ceo and director |
Nov 18, 2022 | meckler jeffrey a | bought | 705 | 1.7637 | 400 | ceo and director |
Sep 08, 2022 | meckler jeffrey a | bought | 28,862 | 2.8 | 10,308 | ceo and director |
Sep 07, 2022 | meckler jeffrey a | bought | 22,184 | 2.57 | 8,632 | ceo and director |
Sep 07, 2022 | linscott walt addison | bought | 393 | 2.62 | 150 | chief business officer |
Which funds bought or sold INDP recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | reduced | -32.87 | -5,183 | 29,284 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | 426 | 1,981 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -5.00 | - | -% |
May 15, 2024 | Vivaldi Capital Management LP | unchanged | - | 11,563 | 51,600 | 0.01% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -13.42 | 843 | 9,108 | -% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -29,237 | - | -% |
May 14, 2024 | Qube Research & Technologies Ltd | unchanged | - | - | 2.00 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | 25,746 | 122,699 | -% |
May 13, 2024 | UBS Group AG | reduced | -47.66 | -2,173 | 4,337 | -% |
Peers (Alternatives to Indaptus Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Indaptus Therapeutics, Inc. News
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -26.6% | 11.00 | 15.00 | 18.00 | 21.00 | 23.00 | 28.00 | 30.00 | 34.00 | 37.00 | 41.00 | 44.00 | 20.00 | 17.00 | 2.00 | 21.00 |
Current Assets | -26.5% | 10.00 | 14.00 | 17.00 | 20.00 | 22.00 | 27.00 | 30.00 | 33.00 | 37.00 | 40.00 | 44.00 | 19.00 | 12.00 | 2.00 | 14.00 |
Cash Equivalents | -27.1% | 10.00 | 13.00 | 16.00 | 13.00 | 7.00 | 10.00 | 7.00 | 14.00 | 33.00 | 39.00 | 42.00 | 17.00 | 10.00 | 2.00 | 9.00 |
Net PPE | -100.0% | - | 735* | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 1.00 | 0.00 | 3.00 |
Liabilities | -44.2% | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 | - | 6.00 | 6.00 | 2.00 | 10.00 |
Current Liabilities | -44.6% | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 | 6.00 | 5.00 | 5.00 | 2.00 | 8.00 |
Shareholder's Equity | -22.5% | 9.00 | 12.00 | 15.00 | 19.00 | 21.00 | 25.00 | 28.00 | 30.00 | 33.00 | 36.00 | 38.00 | 14.00 | 11.00 | 15.00 | 3.00 |
Retained Earnings | -8.4% | -49.22 | -45.42 | -41.40 | -37.49 | -34.20 | -29.99 | -26.30 | -22.90 | -19.04 | -15.67 | -12.45 | -215 | -207 | -7.96 | -189 |
Additional Paid-In Capital | 1.9% | 58.00 | 57.00 | 57.00 | 56.00 | 55.00 | 54.00 | 54.00 | 53.00 | 52.00 | 51.00 | 50.00 | 228 | 218 | 8.00 | 200 |
Shares Outstanding | 1.6% | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 3.00 | 2.00 | 2.00 | 2.00 | - |
Float | - | - | - | - | 13.00 | - | - | - | 15.00 | - | - | - | 26.00 | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | -51.3% | -3,936 | -2,601 | -3,703 | -2,137 | -4,962 | -2,210 | -4,601 | -3,148 | -3,117 | -3,539 | -5,630 | -1,294 | -825 | -957 | 4,449 | -1,670 | -5,147 | - |
Share Based Compensation | 3.9% | 775 | 746 | 765 | 728 | 727 | 638 | 584 | 904 | 831 | 674 | 795 | 21.00 | 20.00 | 23.00 | -739 | 414 | 442 | - |
Cashflow From Investing | - | - | - | 7,000 | 8,000 | 2,141 | 5,120 | -2,939 | -15,809 | -2,798 | 452 | -1.65 | -1.20 | -1.00 | - | - | - | 769 | - |
Cashflow From Financing | - | 316 | - | - | - | - | - | - | - | - | 363 | 42,524 | 1,775 | 3,675 | -3.96 | -9,436 | 4,491 | 6,113 | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 1,591,142 | $ 1,879,900 |
General and administrative | 2,352,097 | 2,575,266 |
Total operating expenses | 3,943,239 | 4,455,166 |
Loss from operations | (3,943,239) | (4,455,166) |
Other income, net | 136,562 | 201,928 |
Net loss | $ (3,806,677) | $ (4,253,238) |
Net loss available to common stockholders per share of common stock, basic | $ (0.45) | $ (0.51) |
Net loss available to common stockholders per share of common stock, diluted | $ (0.45) | $ (0.51) |
Weighted average number of shares used in calculating net loss per share, basic | 8,442,364 | 8,401,047 |
Weighted average number of shares used in calculating net loss per share, diluted | 8,442,364 | 8,401,047 |
Other comprehensive income: | ||
Reclassification adjustment for interest earned on marketable securities included in net loss | $ (129,229) | |
Change in unrealized gain on marketable securities | 210,252 | |
Comprehensive loss | $ (3,806,677) | $ (4,172,215) |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 9,741,638 | $ 13,362,053 |
Prepaid expenses and other current assets | 551,031 | 633,156 |
Total current assets | 10,292,669 | 13,995,209 |
Non-current assets: | ||
Property and equipment, net | 735 | |
Right-of-use asset | 151,118 | 173,206 |
Other assets | 504,728 | 754,728 |
Total non-current assets | 655,846 | 928,669 |
Total assets | 10,948,515 | 14,923,878 |
Current liabilities: | ||
Accounts payable and other current liabilities | 1,434,828 | 2,672,327 |
Operating lease liability, current portion | 102,464 | 101,705 |
Total current liabilities | 1,537,292 | 2,774,032 |
Non-current liabilities: | ||
Operating lease liability, net of current portion | 50,664 | 73,348 |
Total non-current liabilities | 50,664 | 73,348 |
Total liabilities | 1,587,956 | 2,847,380 |
Commitments and contingencies (Note 7) | ||
Stockholders’ equity: | ||
Common stock: $0.01 par value, 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 8,538,883 shares issued and outstanding as of March 31, 2024 and 8,401,047 shares issued and outstanding as of December 31, 2023 | 85,389 | 84,011 |
Additional paid in capital | 58,499,003 | 57,409,643 |
Accumulated deficit | (49,223,833) | (45,417,156) |
Total stockholders’ equity | 9,360,559 | 12,076,498 |
Total liabilities and stockholders’ equity | $ 10,948,515 | $ 14,923,878 |